Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan

References

• Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010;9:402–412.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy. Where we are, where we should go. J Peripher Nerv Syst. 2014;19:2–13.
   PubMed Web of Science ®Google Scholar
• Lunn MPT, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry. 1999;66:677–680.
   PubMed Web of Science ®Google Scholar
• Mahdi-Rogers M, Hughes RAC. Epidemiology of chronic inflammatory neuropathies in south-east England. Eur J Neurol. 2014;21(1):28–33.
   PubMed Web of Science ®Google Scholar
• Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. 2017;88:304–313.
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Allen D, Makowska A, et al. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2006;11:30–46.
   PubMed Web of Science ®Google Scholar
• Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype . J Neurol Neurosurg Psychiatry. 2015;86:973–985.
   PubMed Web of Science ®Google Scholar
• Beriner A, Brannagan TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2014;50(1):40–46.
   PubMed Web of Science ®Google Scholar
• Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst. 2010:15:1–9. Erratum in: J Peripher Nerv Syst. 2010;15:373.
   Web of Science ®Google Scholar
• Dyck PJ, O’Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136–144.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Daube J, O’Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461–465.
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain. 1996;119:1055–1066.
   PubMed Web of Science ®Google Scholar
• Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebo-controlled trial. Lancet Neurol. 2008;7:136–144.
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo controlled study. J Neurol Neurosug Psychiatry. 1993;56:36–39.
   PubMed Web of Science ®Google Scholar
• Thompson N, Choudhary P, Hughes RAC, et al. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 1996;243:280–285.
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double blind, placebo-controlled, cross-over study. Brain. 1996;119:1067–1077.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Barohn S, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56:445–449.
   PubMed Web of Science ®Google Scholar
• Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17:289–294.
   PubMed Web of Science ®Google Scholar
• Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15:50–56.
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Hughes RAC. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;1:CD002062.
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Hughes RAC, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2012;9:CD003906.
   Google Scholar
• Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;12:CD001797.
   Google Scholar
• Oaklander AL, Lunn MPT, Hughes RAC, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews (Review). Cochrane Database Syst Rev. 2017;1:CD010369.
   PubMed Web of Science ®Google Scholar
• Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2012;78:1009–1015.
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Bensa S, Willison HJ, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838–845.
   PubMed Web of Science ®Google Scholar
• Eftimov F, Vermeulen M, Van Doorn PA, et al. Long-term remission of CIDP after pulsed high-dose dexamethasone or short term prednisolone treatment. Neurology. 2012;78:1079–1084.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11:493–502.
   PubMed Web of Science ®Google Scholar
• Van Schaik IN, Eftimov F, Van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind randomised controlled trial. Lancet Neurol. 2010;9:245–253.
   PubMed Web of Science ®Google Scholar
• Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67(7):802–807.
   PubMedGoogle Scholar
• Nobile-Orazio E, Cocito D, Jann S, et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86:729–734.
   PubMed Web of Science ®Google Scholar
• Rabin M, Mutlu G, Stojkovic T, et al. Chronic inflammatory demyelinating polyradiculoneuropathy : search for factors associated with treatment dependence or successful withdrawal. J Neurol Neurosurg Psychiatry. 2014;85:901–906.
   PubMed Web of Science ®Google Scholar
• Press R, Hiew FL, Rajabally YA. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. Acta Neurol Scand. 2016;133:228–238.
   PubMed Web of Science ®Google Scholar
• Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20(5):836–842.
   PubMed Web of Science ®Google Scholar
• Markvardsen LH, Harbo T, Sindrup SH, et al. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2014;21:1465–1470.
   PubMed Web of Science ®Google Scholar
• Cocito D, Merola A, Romagnolo A, et al. Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response? J Neurol Neurosurg Psychiatry. 2016;87(7):791–793.
   PubMed Web of Science ®Google Scholar
• Van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo-controlled trial: the PATH study. Peripheral Nerve Society Meeting, Sitges, Barcelona, July8-12, 2017, J Peripher Nerv Syst 2017; 22 (Supplement) in press.
   Google Scholar
• Markvardsen LH, Sindrup SH, Christiansen I, et al. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. Eur J Neurol. 2017;24:412–418.
   PubMed Web of Science ®Google Scholar
• McCrone P, Chisholm D, Knapp M, et al. Cost-Utility Analysis of Intravenous Immunoglobulin and Prednisolone for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Eur J Neurol. 2003;10:687–694.
   PubMed Web of Science ®Google Scholar
• Mahdi-Rogers M, McCrone P, Hughes RA. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2014;21(1):34–39.
   PubMed Web of Science ®Google Scholar
• Choudhary PP, Hughes RA. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Qjm. 1995;88:493–502.
   PubMed Web of Science ®Google Scholar
• Mahdi-Rogers M, Van Doorn PA, Hughes RAC. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;6:CD003280.
   Google Scholar
• Dyck PJ, O’Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology. 1985;35:1173–1176.
   PubMed Web of Science ®Google Scholar
• RMC Trial Group. Pilot randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC Trial). Lancet Neurol. 2009;8:158–164.
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Gorson KC, Cros D, et al. Intramusculatr interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2010;74:651–657.
   PubMed Web of Science ®Google Scholar
• Hadden RDM, Sharrack B, Bensa S, et al. Randomized trial of interferon β–1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1999;53:57–61.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Dalakas M, Merkies I, et al. Oral fingolimod in chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP): results from a Phase III Randomized Placebo-controlled Trial. American Academy of Neurology 69th Annual Meeting, April 22-28, 2017, Boston, MA (abstract).
   Google Scholar
• Wolf C, Menge T, Stenner MP, et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2010;67:881–883.
   PubMedGoogle Scholar
• Vallat JM, Mathis S, Ghorab K, et al. Natalizumab as a disease-modifying therapy in chronic inflammatory demyelinating polyneuropathy - A report of three cases. Eur Neurol. 2015;73:294–302.
   PubMed Web of Science ®Google Scholar
• Press R, Askmark H, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP. J Neurol Neurosurg Psychiatry. 2014;85:618–624.
   PubMed Web of Science ®Google Scholar
• Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257(6):913–919.
   PubMed Web of Science ®Google Scholar
• Cocito D, Grimaldi S, Paolasso I, et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011;18:1417–1421.
   PubMed Web of Science ®Google Scholar
• Good JL, Chehrenama M, Mayer RF, et al. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;51:1735–1738.
   PubMed Web of Science ®Google Scholar
• Brannagan TH 3rd, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology. 2002;58:1856–1858.
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Prestrud AA, Brannagan TH 3rd. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2005;10:11–16.
   PubMed Web of Science ®Google Scholar
• Benedetti L, Briani C, Fazio R, et al. Rituximab in patients with CIDP: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82:306–308.
   PubMed Web of Science ®Google Scholar
• Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibody to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013;73:370–380.
   PubMed Web of Science ®Google Scholar
• Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014;82:879–886.
   PubMed Web of Science ®Google Scholar
• Miura Y, Devaux JJ, Fukami Y, et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain. 2015;138:1484–1491.
   PubMed Web of Science ®Google Scholar
• Devaux JJ, Miura Y, Fukami Y, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016;86:800–807.
   PubMed Web of Science ®Google Scholar
• Querol L, Rojas-García R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e149.
   PubMed Web of Science ®Google Scholar
• Sabatelli M, Madia F, Mignogna T, et al. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol. 2001;248:772–777.
   PubMed Web of Science ®Google Scholar
• Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778–783.
   PubMed Web of Science ®Google Scholar
• Kimura A, Sakurai T, Koumura A, et al. Motor-dominant chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257:621–629.
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Isose S, Mori M, et al. Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2014;86:1054–1059.
   PubMed Web of Science ®Google Scholar
• Tackenberg B, Lünemann JD, Steinbrecher A, et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology. 2007;68:1622–1629.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve. 2005;31:663–680.
   PubMed Web of Science ®Google Scholar
• Van Asseldonk JT, Franssen H, Van Den Berg-Vos RM, et al. Multifocal motor neuropathy. Lancet Neurol. 2005;4:309–319.
   PubMed Web of Science ®Google Scholar
• Cats EA, Van Der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75:818–825.
   PubMed Web of Science ®Google Scholar
• Olney RK, Lewis RA, Putnam TD, et al. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve. 2003;27:117–121.
   PubMed Web of Science ®Google Scholar
• Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/ Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. First revision. J Peripher Nerv Syst. 2010;15:295–301.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Giannotta C, Musset L, et al. Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2014;85:754–758.
   PubMed Web of Science ®Google Scholar
• Van Es HW, Van Den Berg LH, Franssen H, et al. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology. 1997;48:1218–1224.
   PubMed Web of Science ®Google Scholar
• Kerasnoudis A, Pitarokoili K, Behrendt V, et al. Multifocal motor neuropathy: correlation of nerve ultrasound, electrophysiological, and clinical findings. J Peripher Nerv Sys. 2014;19:165–174.
   PubMed Web of Science ®Google Scholar
• Van Schaik IN, Van Den Berg LH, De Haan R, et al. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005;2:CD004429.
   Google Scholar
• Azulay J-P, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo controlled study. Neurology. 1994;44:429–432.
   PubMed Web of Science ®Google Scholar
• Van Den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;59:248–252.
   PubMed Web of Science ®Google Scholar
• Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled, study. Neurology. 2000;55:1257–1262.
   Web of Science ®Google Scholar
• J-M L, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind placebo-controlled study. Brain. 2001;124:145–153.
   PubMed Web of Science ®Google Scholar
• Hahn AF, Beydoun SR, Lawson V, et al. A phase III randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIg) for the treatment of multifocal motor neuropathy. J Peripher Nerv Syst. 2012;17:243–244.
   Google Scholar
• Azulay JP, Rihet P, Pouget J, et al. Long-term follow-up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry. 1997;62:391–394.
   PubMed Web of Science ®Google Scholar
• Van Den Berg-Vos RM, Franssen H, Wokke JHJ, et al. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain. 2002;125:1875–1886.
   PubMed Web of Science ®Google Scholar
• Vucic S, Black KR, Chong PS, et al. Multifocal motor neuropathy. Decrease in conduction blocks and reinnervation with long-term IVIg. Neurology. 2004;63:1264–1269.
   PubMed Web of Science ®Google Scholar
• Léger JM, Viala K, Cancalon F, et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry. 2008;79:93–96.
   PubMed Web of Science ®Google Scholar
• Terenghi F, Cappellari A, Bersano A, et al. How long is IVIg effective in multifocal motor neuropathy? Neurology. 2004;62:666–668.
   PubMed Web of Science ®Google Scholar
• Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized single-blinded cross-over trial. Eur J Neurol. 2009;16:631–638.
   PubMed Web of Science ®Google Scholar
• Eftimov F, Vermeulen M, De Haan RJ, et al. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009;14:93–100.
   PubMed Web of Science ®Google Scholar
• Umapathi T, Hughes R, Nobile-Orazio E, et al. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev. 2015;4:CD003217.
   Google Scholar
• Piepers S, Van Den Berg-Vos R, Van Der Pol W-L, et al. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain. 2007;130:2004–2010.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Terenghi F, Cocito D, et al. Oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy. J Peripher Nerv Syst. 2009;14:203–205.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Mann CA, Barry S, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16:84–91.
   PubMed Web of Science ®Google Scholar
• Stielgbauer K, Topakian R, Hinterberger G, et al. Beneficial effect of rituximab therapy in multifocal motor neuropathy. Neuromusc Disord. 2009;19:473–475.
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Cornblath DR. An open label trial of rituximab (Rituxan®) in multifocal motor neuropathy. J Peripher Nerv Syst. 2010;15:196–201.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E. Neuropathy and monoclonal gammopathy. In: Said G, Krarup C, Editors. Handbook of clinical neurology. Vol. 115 (3rd series); Peripheral nerve disorders. Vol. 115. Amsterdam, The Netherlands: Elsevier BV; 2013. p. 443–459.
   Google Scholar
• Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J Peripher Nerv Syst. 2010;15:185–195.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relation with immune therapies. Brain. 2000;123:710–717.
   PubMed Web of Science ®Google Scholar
• Niermeijer JMF, Fischer K, Eurelings M, et al. Prognosis of polyneuropathy due to IgM monoclonal gammopathy. Neurology. 2010;74:406–412.
   PubMed Web of Science ®Google Scholar
• Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016;10:CD002827.
   PubMed Web of Science ®Google Scholar
• Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485–489.
   PubMed Web of Science ®Google Scholar
• Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG associated polyneuropathy. Neurology. 2006;66:742–744.
   PubMed Web of Science ®Google Scholar
• Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Periph Nerv Syst. 2007;12:102–107.
   PubMed Web of Science ®Google Scholar
• Niermeijer JM, Eurelings M, Lokhorst HL, et al. Rituximab for polyneuropathy with IgM monoclonal gammopathy. J Neurol Nerosurg Psychiatry. 2009;80:1036–1039.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286–293.
   PubMed Web of Science ®Google Scholar
• Léger JM, Viala K, Nicolas G, et al. Placebo controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80(24):2217–2225.
   PubMed Web of Science ®Google Scholar
• Benedetti L, Briani C, Franciotta D, et al. Long-term effect of rituximab in anti-MAG polyneuropathy. Neurology. 2008;71:1742–1744.
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports project. Blood. 2009;113:4834–4840.
   PubMed Web of Science ®Google Scholar
• Gruson B, Ghomari K, Beaumont M, et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst. 2011;16:180–185.
   PubMed Web of Science ®Google Scholar
• Gomez A, Hoffman JE. Anti myelin-associated-glycoprotein antibody peripheral neuropathy response to combination chemoimmunotherapy with bendamustine/rituximab in a patient with biclonal IgM k and IgM λ: case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2016;16(7):e101–8.
   PubMed Web of Science ®Google Scholar
• Codron P, Cousin M, Subra JF, et al. Therapeutic plasma exchange in chronic dysimmune peripheral neuropathies: a 10-year retrospective study. J Clin Apher. 2017 Mar 1. [Epub ahead of print]. doi:10.1002/jca.21530
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Gallia F, Terenghi F, et al. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci. 2008;266:156–163.
   PubMed Web of Science ®Google Scholar
• Magy L, Kaboré R, Mathis S, et al.Heterogeneity of polyneuropathy associated with anti-MAG antibodies. J Immunol Res. 2015. Article ID 450391.
   PubMed Web of Science ®Google Scholar
• Gallia F, Balducci C, Nobile-Orazio E. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune mediated neuropathies. J Peripher Nerv Syst. 2016;21(2):82–84.
   PubMed Web of Science ®Google Scholar